Table 5 a, Association between outcome (Relapse vs. NED) and dichotomized biomarkers at baseline. b, Association of baseline dichotomized biomarkers with irAE (Yes vs. No) for a total 55 patients
From: Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Biomarker | Outcome | n (%) | Odds Ratio | Fisher |
|---|---|---|---|---|
| Â | Â | Â | (95% CI) | p-value |
a. Association between outcome (Relapse/NED) and dichotomized baseline biomarkers by median | ||||
%-Ki67 + EOMES + CD8+ (n = 39) |  |  | 11.25 ( 2.52, 50.27) | 0.0012 |
<=2.11 | Relapse | 15 ( 75.0) | Â | Â |
<=2.11 | NED | 5 ( 25.0) | Â | Â |
2.11 | Relapse | 4 ( 21.1) | Â | Â |
>2.11 | NED | 15 ( 78.9) | Â | Â |
%-EOMES + CD8+ (n = 54) |  |  | 3.77 ( 1.16, 12.27) | 0.0473 |
<=55.6 | Relapse | 14 ( 51.9) | Â | Â |
<=55.6 | NED | 13 ( 48.1) | Â | Â |
>55.6 | Relapse | 6 ( 22.2) | Â | Â |
>55.6 | NED | 21 ( 77.8) | Â | Â |
b. Association between irAE (Yes/No) and dichotomized baseline biomarkers by median | ||||
%-Ki67 + EOMES + CD4+ (n = 39) |  |  | 8.00 ( 1.74, 36.70) |  0.0079 |
<=0.446 | Yes | 12 ( 60.0) | Â | Â |
<=0.446 | No | 8 ( 40.0) | Â | Â |
>0.446 | Yes | 3 ( 15.8) | Â | Â |
>0.446 | No | 16 ( 84.2) | Â | Â |